10.21.10
Ricerca Biosciences Announces Senior Leadership in DMPK, William DeMaio, Ph.D.
(Concord, OH; October 21, 2010) – Ricerca Biosciences, a preclinical contract research organization (CRO) providing services to the biopharmaceutical industry, is pleased to announce the addition of William DeMaio, Ph.D., as senior director of the drug metabolism and pharmacokinetics (DMPK) department.
Dr. DeMaio joins a team of bioanalytical and drug metabolism scientists that provides a unique combination of integrated pharmaceutical development services and analytical problem solving capabilities, offering support for Ricerca’s discovery and preclinical development programs.
“Dr. DeMaio has an international reputation as one of the pharmaceutical industry’s best mass spectrometrist and metabolism scientists,” stated Dr. Michael Placke, senior vice president and general manager of Ricerca’s Concord, Ohio, drug development operations. “Bill has solved most challenges one is likely to encounter in characterizing drug product exposure and metabolizing identification in both non-clinical and clinical settings.”
Prior to joining Ricerca, Dr. DeMaio was associate director of biotransformation at Wyeth Research (now Pfizer) in Collegeville, Pennsylvania, where he was responsible for drug metabolite identification and metabolism characterization by mass spectrometry. Dr. DeMaio has expertise in chromatography, mass spectrometry, structural elucidation and drug development, as well as operating GLP-compliant bioanalytical and metabolism operations and training analysts in use of LC/MS equipment and data analysis.
Dr. DeMaio earned a Ph.D. in chemistry from the University of Houston and a Bachelor of Science in chemistry from Pennsylvania State University, located in University Park, Pennsylvania. He has authored presentations, publications and patents, and is active in public service.
Ricerca offers a unique spectrum of services for the areas of preclinical discovery and development for biopharmaceutical registration, as well as agrochemical and environmental analyses.
About Ricerca Biosciences
Ricerca Biosciences, LLC, offers a comprehensive suite of discovery, preclinical and development services to support drug candidates from discovery through IND and NDA on a global scale. Capabilities include molecular through in vivo screening and profiling, medicinal chemistry, IND-enabling toxicology, API process chemistry and cGMP manufacturing of clinical and commercial API. At Ricerca, our scientific excellence and reliable, cost-effective strategies help accelerate your drug discovery programs via our U.S. based facilities in Concord, Ohio, and Bothell, Washington, and our ISO 9001-certified facilities in Taipei, Taiwan, and Lyon, France. The Lyon and Bothell facilities also hold AAALAC certification.